Insiders · RVPH

Laxminarayan Bhat

President and CEO, Director at Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Laxminarayan Bhat has filed 4 insider reports with the SEC since April 2023, as president and CEO and director at Reviva Pharmaceuticals Holdings, Inc. (RVPH). The latest filing, on March 20, 2026, reports grant or award at Reviva Pharmaceuticals Holdings, Inc. (RVPH).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Laxminarayan Bhat is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Reviva Pharmaceuticals Holdings, Inc. logo
RVPH
Reviva Pharmaceuticals Holdings, Inc.
President and CEO, Director$0.3521Mar 20, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Laxminarayan Bhat with

Other insiders at the same companies

Questions about Laxminarayan Bhat

What is Laxminarayan Bhat's role at Reviva Pharmaceuticals Holdings, Inc.?
Laxminarayan Bhat reports to the SEC as president and CEO and director at Reviva Pharmaceuticals Holdings, Inc. (RVPH), according to the latest filing on March 20, 2026.
Has Laxminarayan Bhat bought or sold stock recently?
No open-market purchases or sales by Laxminarayan Bhat are on file. The filings report grant or award.
How do I get alerts when Laxminarayan Bhat files?
Follow Laxminarayan Bhat on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Laxminarayan Bhat (SEC CIK 0001818245). Totals count each trade once, skipping amendments whose original is on file, from Apr 27, 2023 on. View on SEC EDGAR